SCHEMBL5456859

SCHEMBL5456859

COC(=O)C(C)CP(=O)(O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 4/20 0.38
MMP2 P08253 3/20 0.38
MMP8 P22894 3/20 0.38
CA12 O43570 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA9 Q16790 2/20 0.38
MMP9 P14780 1/20 0.38
MMP3 P08254 1/20 0.38
CA14 Q9ULX7 2/20 0.35
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
KMT2A Q03164 1/20 0.35
FDPS P14324 1/20 0.34
FOLH1 Q04609 3/20 0.34
GABBR2 O75899 1/20 0.33
GABBR1 Q9UBS5 1/20 0.33
FNTA P49354 1/20 0.33
FNTB P49356 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2466027 0.86 MMP1 (0.38) MMP1MMP2MMP8CA12SMN1; SMN2
SCHEMBL2403902 0.84 GABRR1 (0.39) MMP1MMP2MMP8CA12SMN1; SMN2
SCHEMBL15259072 0.83 MMP1 (0.35) MMP1MMP2MMP8CA12SMN1; SMN2
SCHEMBL8565444 0.82 SMN1; SMN2 (0.38) MMP1MMP2MMP8CA12SMN1; SMN2
SCHEMBL8565442 0.82 SMN1; SMN2 (0.38) MMP1MMP2MMP8CA12SMN1; SMN2
SCHEMBL8558146 0.82 SMN1; SMN2 (0.38) MMP1MMP2MMP8CA12SMN1; SMN2
SCHEMBL2352012 0.81 MMP1 (0.38) MMP1MMP2MMP8CA12SMN1; SMN2
SCHEMBL8558409 0.80 SMN1; SMN2 (0.37) MMP1MMP2MMP8CA12SMN1; SMN2
SCHEMBL8558408 0.80 SMN1; SMN2 (0.37) MMP1MMP2MMP8CA12SMN1; SMN2
SCHEMBL9697205 0.79 ANPEP (0.35) MMP1MMP2MMP8CA12SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114539085-B Preparation of ureido derivatives 山东诚创蓝海医药科技有限公司 2023-10-20 CN disclosed
CN-105009349-B Lithium secondary battery 日立麦克赛尔株式会社 2017-09-05 CN disclosed
US-20070054902-A1 Isoxazole derivatives as peroxisome proliferator-activated receptors agonists SHIONOGI & CO., LTD. (JP) 2007-03-08 US disclosed
EP-1690538-A1 ISOXAZOLE DERIVATIVE HAVING AGONISTIC ACTIVITY AGAINST PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR SHIONOGI & CO., LTD. (JP) 2006-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054902-A1 Isoxazole derivatives as peroxisome proliferator-activated receptors agonists NR1H3, NR1H2, RXRA MMP1 3752/4885MMP2 3611/4885MMP8 3304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.